Literature DB >> 8389191

Finasteride: a slow-binding 5 alpha-reductase inhibitor.

B Faller1, D Farley, H Nick.   

Abstract

A microsomal preparation of human prostatic tissue was used to study the kinetics of interaction of steroid 5 alpha-reductase with finasteride, a known 5 alpha-reductase inhibitor. This molecule has been reported to reversibly bind 5 alpha-reductase in a competitive manner to testosterone with a Ki value in the 10 nM range. The results presented in this paper show that enzyme-inhibitor complex formation does not take place instantaneously as assumed in previous studies. At neutral pH and 37 degrees C, the association of enzyme with inhibitor is governed by a rate constant, kon, of 2.7 x 10(5) M-1 s-1. This low kon value, in combination with the high energy of activation of the association reaction (150 kJ mol-1), indicates that the association process is not diffusion controlled and may proceed through intermediate steps. However, such an intermediate was not detected kinetically under the inhibitor concentrations investigated. We therefore conclude that the equilibrium dissociation constant, Ki*, for the initial binding of the enzyme to the inhibitor is higher than 1.5 x 10(7) M. Even at inhibitor concentrations as low as 1 nM, the reaction was completely displaced to the EI complex and no residual activity detected once the equilibrium was reached. Hence, the interaction between finasteride and 5 alpha-reductase can also be characterized by a very low overall equilibrium dissociation constant (Ki << 10(-9) M), at least 1 order of magnitude lower than previously reported values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389191     DOI: 10.1021/bi00072a028

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

2.  Kinetic and inhibition studies of dihydroxybenzoate-AMP ligase from Escherichia coli.

Authors:  Alison L Sikora; Daniel J Wilson; Courtney C Aldrich; John S Blanchard
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

3.  In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation.

Authors:  Alba A Chavez-Dozal; Livia Lown; Maximillian Jahng; Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 4.  Targeting 5α-reductase for prostate cancer prevention and treatment.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

Review 5.  Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics and pharmacodynamics of finasteride.

Authors:  J F Steiner
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

7.  5α-Reductase Isozymes in the Prostate.

Authors:  Yuan-Shan Zhu; Guang-Huan Sun
Journal:  J Med Sci       Date:  2005

8.  Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.

Authors:  Yue Wu; Alejandro Godoy; Faris Azzouni; John H Wilton; Clement Ip; James L Mohler
Journal:  Prostate       Date:  2013-06-27       Impact factor: 4.104

9.  The 5α-reductase inhibitor finasteride reduces opioid self-administration in animal models of opioid use disorder.

Authors:  Gabriel D Bosse; Roberto Cadeddu; Gabriele Floris; Ryan D Farero; Eva Vigato; Suhjung J Lee; Tejia Zhang; Nilesh W Gaikwad; Kristen A Keefe; Paul Em Phillips; Marco Bortolato; Randall T Peterson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

10.  Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity.

Authors:  M F Palin; M Faguy; J G LeHoux; G Pelletier
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.